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Dendritic cells (DCs) and monocytes are critical regulators and effectors of innate and
adaptive immune responses. Monocyte expansion has been described in many pathologi-
cal states while monocyte and DC deficiency syndromes are relatively recent additions to
the catalog of human primary immunodeficiency disorders. Clinically applicable screening
tests to diagnose and monitor these conditions are lacking. Conventional strategies for
identifying human DCs and monocytes have been based on the use of a lineage gate to
exclude lymphocytes, thus preventing simultaneous detection of DCs, monocytes, and
lymphocyte subsets. Here we demonstrate that CD4 is a reliable lineage marker for the
human peripheral blood antigen-presenting cell compartment that can be used to identify
DCs and monocytes in parallel with lymphocytes. Based on this principle, simple modifi-
cation of a standard lymphocyte phenotyping assay permits simultaneous enumeration of
four lymphocyte and five DC/monocyte populations from a single sample.This approach is
applicable to clinical samples and facilitates the diagnosis of DC and monocyte disorders in
a wide range of clinical settings, including genetic deficiency, neoplasia, and inflammation.
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INTRODUCTION
Dendritic cells (DCs) and monocytes are bone marrow derived
mononuclear cells involved in a wide range of immune functions.
Blood DCs comprise three subsets: plasmacytoid DCs (pDCs),
CD1c+ myeloid DCs (mDCs), and CD141+ mDCs (1–5). pDCs
typically lack the myeloid antigens CD13, CD33, and CD11b and
express CD123 (IL-3 receptor), CD303 [CLEC4C; Blood DC anti-
gens (BDCA)-2], and CD304 (neuropilin; BDCA-4) (1). They are
specialized to produce a rapid type I interferon response to viral
infections (6). mDCs share markers in common with monocytes
and granulocytes including CD13, CD33, and CD11b and perform
the classical functions of DCs in taking up and presenting anti-
gen on HLA class II molecules. DCs resembling all three subsets
are found in lymph nodes (7, 8) both mDC subsets have tissue
counterparts (5).
Monocytes also comprise a number of distinct functional sub-
sets delineated by expression of CD14 and CD16 in humans.
CD14+ CD16− “classical monocytes” perform inflammatory
functions including phagocytosis, production of reactive oxygen
species, nitric oxide, and TNFα (9). Two additional populations
have been described: CD16+ CD14low “non-classical” monocytes
and CD14+ CD16+ “intermediate” monocytes (3, 10). There is
variation in how these cells are divided, with a position paper
on nomenclature suggesting that intermediate monocytes may be
grouped with non-classical monocytes (both linked by the expres-
sion of CD16) while more recent gene expression studies suggest
that intermediate monocytes are more closely linked to classical
monocytes (11). Both by flow cytometry and gene set enrich-
ment analysis, intermediate monocytes appear to be part of a
continuum (12). It is clear, however, that the non-classical pole
of the spectrum contains cells with higher class II expression, allo-
stimulatory capacity, and cytokine production that have led to
their classification as a type of DC (2, 13). CD16+ non-classical
monocytes are also smaller and become closely associated with
the endothelium upon adoptive transfer into mice (11). A wide
range of studies show that non-classical monocytes are increased
by exercise, autoimmune disease, bacterial sepsis, tuberculosis, and
HIV infection, reviewed in Ref. (10).
Routine analysis of human blood DCs and monocytes is usually
confined to the enumeration of classical monocytes by automated
blood counters. The complexity of changes in DC and monocyte
subsets is not visible in most clinical scenarios. Flow cytometry is
frequently used to analyze lymphocyte subsets but simultaneous
detection of DCs and monocytes is hampered by the lack of a
positive lineage marker. Although robust platforms for DC count-
ing have been described, these invariably depend upon identifying
MHC class II (HLA-DR) expression by lineage (lin) negative cells,
a population defined by the exclusion of T cells (CD3), B cells
(CD19, CD20), NK cells (CD56), monocytes (CD14, CD16), and
progenitors (CD34) (2, 14, 15). The exclusion of lin+ lympho-
cytes and monocytes either precludes simultaneous measurement
with DCs or demands large number of fluorescence channels (4,
15). Differential DC and monocyte counting is therefore rarely
performed as a clinical test.
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Blood DC antigens 1–4 are helpful for identifying human DC
subsets (1) but are often used to define pDC and mDC subsets
within the HLA-DR+ lin− population (4, 16). This is especially
true for CD1c (BDCA-1), which identifies the main population
of mDCs but is also expressed on B cells (1). CD303 (BDCA-2;
CLEC4C) and CD304 (BDCA-4; neuropilin) are relatively robust
markers for pDCs and give reliable counting even from unselected
peripheral blood mononuclear cells. CD141 (BDCA-3) defines a
very small population of mDCs (1, 2).
Early reports demonstrated that DCs and monocytes both
express CD4, but at lower levels than T helper cells (17–19). While
the CD4 glycoprotein acts as a co-receptor for the T cell recep-
tor on T helper cells, its role on myeloid cells is less clear. CD4
also functions as a receptor for IL-16 (lymphocyte chemoattrac-
tant factor), which is capable of both recruiting CD4+ immune
cells and driving cell growth (20). Studies in HIV suggest that
CD4 may augment Fc receptor signaling (21). Numerous studies
report the presence of CD4 on myeloid hematopoietic precursors
including myeloid malignancies (22). While in mice, expression
of CD4 is retained by T lymphocyte and myeloid precursors but
lost by B lymphocyte precursors (23), the function and fate of
CD4 expressing precursors in humans has not been adequately
mapped.
Here we show that CD4 has significant utility as positive lin-
eage marker of human blood antigen-presenting cells, allowing
delineation of all the currently recognized subsets of human
blood monocytes and DCs. This allowed us to adapt a standard
6-color flow cytometry protocol for lymphocyte immunopheno-
typing to allow simultaneous quantification of DC and monocyte
subsets.
MATERIALS AND METHODS
PARTICIPANTS
For assay development, blood was collected into EDTA from 33
patients and 5 healthy controls. Patients were randomly selected
from the regional clinical immunology laboratory. Patients were
aged 2–83 (median 44) and had unknown conditions for further
investigation [11], immunodeficiency [7], autoimmunity [7], or
atopy [3]. To test the assay in pathological states, fresh blood
was obtained from a 33-year old man with DCML deficiency
due to GATA-2 deficiency and a 77-year old man with blastic
plasmacytoid dendritic cell neoplasm (BPDCN). To recapitulate
septic conditions with left-shifted myelopoiesis, eight samples
of cryopreserved G-CSF-mobilized peripheral blood stem cells
(PBSC) were thawed and washed for analysis. Ethical approval
was granted by Newcastle and North Tyneside Research Ethics
Committee 1.
PROCESSING AND ANALYSIS
TruCount™ tubes (Becton Dickinson; BD) containing a defined
number of polyfluorescent beads per test were used in a single step
“lyse-no wash” method to enumerate blood cells, according to the
manufacturer’s instructions. Fifty microliters of blood was trans-
ferred directly to the TruCount™ tube. Antibodies were added
directly and staining was performed at 4°C for 20 min. Red cell lysis
was achieved by addition of 450µl of the proprietary reagent at
room temperature for 10 min. Samples were then directly analyzed
by flow cytometry and the number of cells per microliters of blood
was calculated from the number of events and the fraction of beads
analyzed, according to the formula:
Cells/µl of population x = (population x events/bead events)
× (beads per test/50)
The TBNK reagent (BD catalog number 337166) contains six
reagents as described in Table 1 for the detection of CD45, CD3,
CD4, CD8, CD19, and CD16/56. Combined with TruCount tubes
this reagent allows the enumeration of CD4+ and CD8+ T cells,
B cells, and NK cells. The modification for detecting DCs and
monocytes was to add CD14-APC-Cy7 to the CD8 channel and
CD304-APC to the CD19 channel.
Flow cytometry was performed on FACSCanto two or three
laser instruments running DiVa version 6 (BD). Instrument PMTs
were set using whole blood stained with single antibodies. FSC and
SSC thresholds were set at zero to in order to capture TruCount™
bead events. A threshold was set on CD45, allowing detection of
leukocytes, but discounting platelet and red cell debris. Thresh-
olds were 1000 on 635 780/60 channel for the 8-color panel
and 1000 on 488 760LP channel for the 6-color panel. Isotype
controls were performed for all antibodies at the initial set up
and are shown specifically for CD4. Automatic compensation
was performed using compensation beads (BD). Approximately
200,000 CD45+ events were acquired per sample (Table 2). Analy-
sis was performed with FlowJo version 9.5.2 (TreeStar). Graph-
ing and statistical analysis were performed with Prism version 6
(GraphPad).
Table 1 | Antibody panels used for flow cytometry analysis.
Fluorochrome 8-Color DC panel Modified 6-color panel
FITC CD3 a(345763; BD) CD3
CD19 (345776; BD)
CD20 (345792; BD)
CD56 (345811; BD)
PE CD16 (555407; BD) CD16, CD56
PERCPCy5.5 CD123 (558714; BD) CD45
PECy7 CD14 (557742; BD) CD4
APC CD141 (130-090-907;
Miltenyi)
CD19
CD304 (130-090-900; Miltenyi)
APCCy7 CD14 (557742; BD) CD8
CD14 (557831; BD)
V450 CD11c (560369; BD)
V500 HLA-DR (561224; BD)
a(Catalog number; supplier).
CD4 V500 (560768; BD), CD4 PE (555347; BD), CD3 PE (345765; BD), CD19 PE
(555413; BD), and CD56 PE (345812; BD) were used in additional experiments.
Bold text indicates the antibodies added to modify the 6-colour TBNK(TM) panel
(337166; BD).
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Table 2 | Flow cytometry events recorded for analysis of monocyte
and DC subsets.
Cell population 8-Color DC panel
events collected
median (IQ range)
Modified 6-color panel
events collected
median (IQ range)
DC PANEL COMPARISON (N =24)
Total 204634 (125021) 197925 (101726)
CD14 monocytes 24422 (13512) 9289 (5981)
CD16 monocytes 1590 (2973) 570 (934)
CD14 CD16 monocytes 1381 (1443) 633 (499)
DC 971 (697) 369 (327)
DC SUBSET DISCRIMINATION (N =14)
Total 112172 (39906) 130255 (116775)
mDC 408 (218) 239 (98)
pDC 154 (295) 81 (190)
RESULTS
CD4 IS A LINEAGE MARKER FOR BLOOD ANTIGEN-PRESENTING CELLS
We designed a flow cytometry panel to examine known subsets
of monocytes and DCs. Working with whole blood, the standard
approach of lineage exclusion and HLA-DR selection required a
minimum of eight fluorescence channels to categorize all mono-
cyte and DC subsets. Throughout the study we used this 8-color
panel as the standard reference panel for DC and monocyte enu-
meration (Figure 1A). In the CD45+ SSClow gate, we first gated
on HLA-DR+ lineage negative cells (CD3, CD19, CD20, CD56) to
obtain all the monocyte and blood DC populations. Monocytes
were analyzed by CD14 vs. CD16 and the double negative cells
further separated into pDCs and two subsets of mDCs. We then
explored the expression of CD4 on different leukocytes. We used
specific fluorophores to identify each lineage-positive fraction and
the schema outlined in Figure 1A to identify DCs and monocytes.
CD4+ T cells are seen in the CD3+ fraction but B cells and NK
cells are CD4 negative (Figure 1B). Back-gating illustrates where
each population lies on the HLA-DR vs. lineage plot. This indi-
cates that NK cells are most likely to broach the lin-DR+ gate. As
many NK cells express CD16, the gate must be placed sufficiently
low on the lineage axis to prevent subsequent NK contamination
of the CD16 monocyte gate. All monocyte and DC populations
express CD4 above isotype control (Figures 1C,D). Back-gating
shows the relative HLA-DR expression of these populations. The
position of the HLA-DR vs. lineage gate is critical as some mono-
cytes express low HLA-DR. The lower border of the gate on the
HLA-DR axis was judged according to isotype controls for HLA-
DR (not shown) and the inclusion of a maximum number of
CD14+ monocytes, the cells with the lowest HLA-DR expression.
To ensure that all monocytes and DCs were being captured by this
strategy, the gate was also drawn simply as a lineage negative gate
(Figure S1 in Supplementary Material). Although this results in the
inclusion of HLA-DR negative myeloid precursors and basophils
(4), these are subsequently excluded out by the down-stream gat-
ing on monocytes and DCs. This at least confirms that no cells
are lost by the HLA-DR+ lineage negative gate as it was defined in
Figure 1A.
CD4 EXPRESSION IDENTIFIES MONOCYTES AND DCs WITHIN A
LYMPHOCYTE PHENOTYPING PANEL
Having established the expression of CD4 by different leuko-
cytes, we explored the ability of this marker to capture DCs
and monocytes. The previous results predicted that a 2D plot
of CD4 vs. CD3 should display a population of CD4+ CD3−
cells containing DCs and monocytes, with slightly lower CD4
expression than CD4+ T cells. Both these markers are found
within a standard lymphocyte phenotyping panel, offering the
potential to enumerate DCs monocytes and lymphocytes simul-
taneously. We used the TBNK™ reagent (BD) containing six col-
ors to detect T, B, and NK lymphocytes and provide CD4:CD8
ratios from a single tube. As with the previous panel, mononu-
clear cells are initially separated from granulocytes, beads and
debris by FSC and SSC properties (Figure 2A) and CD45+
cells selected (not shown). The subsequent 2D plot of CD4
vs. CD3 shows the predicted population of CD4+ CD3− cells
(Figure 2B) that does not contain B cells (Figure 2C) or NK cells
(Figure 2D).
To characterize these cells further, we modified the TBNK
reagent by re-using fluorescence channels that had already been
excluded by the gating, namely APC (conjugated to CD19) and
APCCy7 (conjugated to CD8). CD14 APCCy7 in combination
with CD16/56 thus allows resolution of monocyte subsets and
the CD14− CD16− parameter space, containing DCs (Figure 2E).
Note that the CD4+ CD16+ population identified in Figure 2D
is confirmed as the CD16+ non-classical monocyte by low to
medium expression of CD14. Further display of the CD14−
CD16− population by CD4 vs. CD304-APC enabled the assay
to differentiate between mDCs and pDCs (Figures 2F,G). This
also confirms that pDCs have the highest CD4 expression among
DCs and monocytes. The TBNK reagent and its modification are
detailed in Table 1.
THE MODIFIED TBNK PANEL PROVIDES ACCURATE ENUMERATION OF
MONOCYTES AND DCs
To provide a proof-of-concept that modification of the 6-color
TBNK reagent with CD14 APCCy7 could reproduce the enumer-
ation of DCs and monocytes, we ran 24 samples in parallel with
the standard 8-color panel (using HLA-DR vs. lineage as an initial
gate). A further 14 samples were run including both CD14 APCCy7
and CD304 APC with the TBNK reagent to evaluate the ability to
split DCs into pDCs and mDCs. To reproduce the conditions of
a clinical test as closely as possible, we took samples referred to
the regional clinical immunology lab and prepared and analyzed
them independently on separate machines.
Both panels were run using TruCount tubes to achieve absolute
quantification per microliters of blood. Results from the modified
TBNK reagent were highly correlated with those of the standard
8-color panel. The least correlated results were produced for total
DCs and mDCs. This is probably due to the fact that the 6-color
strategy did not include a positive marker of mDCs (except for
CD4); they were defined by the exclusion of other populations
so it is possible for a variable low level of contaminating cells to
be included. Approximately 200,000 total events were recorded
in order to collect at least 100 events for rare subsets of DCs
(Table 2).
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FIGURE 1 | CD4 is differentially expressed on monocytes and DCs. (A) In
an 8-color DC profiling panel FSC and SSC parameters are used to distinguish
mononuclear cells from granulocytes, counting beads, and debris.
Mononuclear cells are confirmed as CD45+ SSC low (gate not shown).
Lineage markers (CD3, 19, 20, 56) are used to remove T, B, and NK cells from
analysis and DR+ monocytes and DCs are selected. The CD14 vs. CD16 plot
reveals three subsets of monocytes and CD14− CD16− DCs. Plasmacytoid
DCs are defined as CD11clow CD123+. Two subsets of CD11c myeloid DC are
split by CD141. Percentage values shown indicate the proportion of gated
cells relative to CD45+ SSC low cells. (B) CD3+ T cells (black), CD56+ NK cells
(green), and CD19+ B cells (blue) are back-gated onto the lineage vs. DR plot
to demonstrate the locations of these populations. Expression of CD4 was
then tested (colored histograms) relative to isotype control (gray). Note that a
small population of activated DR+ CD4+ T cells overlaps the B cell population.
(C) CD14+ monocytes (black), CD16+ monocytes (green), and CD14+16+
monocytes (blue) are back-gated onto the lineage vs. DR plot. Expression of
CD4 is shown (colored histograms), relative to isotype control (gray).
(D) Myeloid DC (green) and plasmacytoid DC (blue) are back-gated onto the
lineage vs. DR plot. Expression of CD4 is shown (colored histograms), relative
to isotype control.
DETECTION OF DC AND MONOCYTE DISORDERS IN CLINICAL
SPECIMENS
To further test the clinical utility of the modified TBNK reagent,
we selected two cases where highly abnormal numbers of DC and
monocytes were detected using the 8-color panel and re-examined
them with the modified TBNK test. The results are plotted on
Figure 3.
Case 1
A 33-year-old man presented to rheumatology with a history
of pyogenic infections, chronic papillomatosis, and recurrent
erythema nodosum. Automated blood counts were normal except
for a monocyte count 0.03× 109/l. DC, monocyte B, and NK
lymphoid (DCML) deficiency was suspected and GATA-2 muta-
tion subsequently confirmed by sequencing (24). A blood sample
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FIGURE 2 | Using CD4 as a lineage marker allows monocytes and DCs
to be counted with a 6-color immunophenotyping panel. (A) In a
6-color immunophenotyping panel modified by addition of CD14 antibody,
mononuclear cells are gated based on FSC and SSC parameters. (B) CD3
negative cells, including DCs and monocytes, B cells and NK cells are
gated out from T cells. (C) CD19+ B cells are removed from the CD3−
population. (D) CD16+ CD56+ NK cells are removed from analysis and the
CD4+ population selected. (E) Visualized on a CD14 vs. CD16 plot, the
CD4+ population contains three subsets of monocytes and CD14− CD16−
DC. (F) Adding CD304 antibody to the assay allows further separation of
the CD14− CD16− DC population into (G) CD4+ CD304− mDCs and
CD4bright CD304+ pDCs.
obtained during routine clinical monitoring was analyzed with
the modified TBNK panel (Figure 3C). Significant and parallel
depletion of all monocyte and DC subsets was observed by both
methods.
Case 2
A 77-year-old man presented to dermatology with progressive
skin nodules and plaques. Immunohistochemistry of a skin biopsy
revealed a dense infiltrate of mononuclear cells positive for CD4,
CD56, and CD123 consistent with a diagnosis of BPDCN. The
leukemic expansion of pDCs was evident with both 8-color and
modified TBNK (Figure 3D) tests. In addition,a relative expansion
of intermediate and non-classical monocytes was also found by
both methods. In the pDC analysis, the 8-color method appeared
to underestimate; we attribute this to the expression of CD56 by
BPDCN which caused some cells to be lost from the HLA-DR+
lineage− gate as they shifted into the lineage+ fraction. In this case,
using CD4 as a positive DC marker proved to be a more reliable
approach.
ENUMERATION OF DCs AND MONOCYTES IN INFLAMMATORY STATES
Septic shock and other inflammatory conditions are associated
with an expansion of monocytes bearing lower HLA-DR. We
therefore explored whether detecting monocytes and DCs by CD4
expression would circumvent the problem of counting cells with
low HLA-DR expression in an HLA-DR+ lineage− gate, or be
subject to similar pitfalls. As a model of septic shock we took
samples of G-CSF mobilized peripheral blood cells, which also
show expanded monocytes with low HLA-DR, and compared
counts derived from the two panels. The HLA-DRlow fraction of
the DC/monocyte gate also expressed lower CD4 (Figures 4A,B)
but as with the HLA-DR+ lineage− gating approach (Figure S1
in Supplementary Material), it was possible to extend the lower
limit of the gate to include the cells with lower expression of CD4
(Figure 4C) resulting in positively correlated results between the
two methods (Figure 4D).
DISCUSSION
In this study we show that CD4 expression may be used within a
lymphocyte typing panel to identify DCs and monocytes and that
this has clinical utility in enabling the simultaneous detection of
nine subsets of lymphocytes, monocytes, and DCs with only six
flow cytometry channels.
Dendritic cells and monocytes have been known to express
CD4 since the early descriptions of blood DCs and from studies
of infectivity by HIV (17–19) but recent strategies for analysis of
DCs and monocytes have typically relied upon resolving HLA-
DR+ lineage− cells (3, 4). CD4 has been used in combination
with a lineage cocktail to identify DCs but lymphocytes are still
excluded by this approach (16). The use of CD4 as a positive lineage
www.frontiersin.org December 2013 | Volume 4 | Article 495 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jardine et al. Detection of human DC and monocyte disorders
FIGURE 3 |The modifiedTBNK assay allows rapid quantitation of APC
subsets, consistent with conventional methods. (A) Correlation between
monocyte and DC counting performed using the 6-color immunophenotyping
panel modified by addition of CD14 vs. the standard 8-color DC panel (n=24).
Red dots indicate results for case 1 (DCML deficiency). Green dots indicate
case 2 (BPDCN). Linear regressions, r 2 and p values stated on the plots
exclude these outlier cases. (B) Correlation between mDC and pDC counting
using the 6-color panel modified with CD14 and CD304 vs. the standard
8-color DC panel (n=14). (C) The modified TBNK assay applied to case 1
(DCML deficiency). Note the scarcity of CD3− cells relative to CD3+ T cells.
This arises from reduction in B cells, absence of NK cells, and virtual absence
of all monocyte and DC subsets. The small population of CD3− CD4bright cells
gated out in the initial plot are activated T cells with reduced CD3 expression.
(D) The modified TBNK assay applied to case 2 (BPDCN).
marker, in combination with CD3, preserves the identification
of lymphocyte subsets. Multiplexing fluorescence channels with
more than one antibody appears to be a reliable means of expand-
ing the number of parameters. Although we cannot exclude that
aberrant expression of surface markers in some conditions may
distort the analysis, this is true of any flow cytometry assay and our
modified 6-color strategy actually enhanced the detection of the
malignant CD4+ CD56+ pDC clone compared with an HLA-DR
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FIGURE 4 | CD4 is expressed on both DR low and DR bright populations
following G-CSF mobilization.The modifiedTBNK assay allows clear
discrimination of lymphocyte, monocyte, and DC populations in
left-shifted blood. (A) The lineage DR plot used for 8-color DC profiling
shows DRbright and DRlow populations of monocytes and DCs in G-CSF
mobilized blood. (B) CD4 expression is highest on lin− DRbright cells but also
positive on lin− DRlow cells. (C) The modified TBNK assay applied to G-CSF
mobilized peripheral blood stem cells (PBSC) permits effective discrimination
of lymphocyte, monocyte, and DC populations. (D) Correlation between
8-color and modified TBNK methods for DCs and monocytes in PBSC.
vs. lineage approach. Employing a single standard mononuclear
cell profiling panel and multiplexing antibodies is likely to prove
especially beneficial where resources and flow cytometry parame-
ters are restricted, as in many clinical service laboratories. Here we
provide proof-of-concept but additional validation and generation
of local normal ranges will be required for clinical use.
This type of assay will be useful for identifying DC deficiency
as recently described in a number of novel human syndromes
(24–26). A typical approach to identifying immunodeficiency uses
screening investigations to refine the differential diagnosis fol-
lowed by more specialist investigations to specify the defect (27).
The capacity to enumerate monocytes and DCs as part of an exist-
ing lymphocyte immunophenotyping platform, is an important
addition to the screening repertoire. Between the 2009 and 2011
revision of the IUIS Primary Immunodeficiency Classification,
7 of the 15 new disease entities concerned the myeloid antigen-
presenting cell compartment (28). The development of means to
rapidly enumerate DCs and monocytes is therefore an unmet need
of clinical importance (29).
Expansion of specific monocyte subsets has been observed
in infection and inflammation in many clinical contexts. The
delineation of monocytes is not always straightforward in relation
to other cells such as NK cells through the expression of CD56 (30)
or owing to the loss of HLA-DR expression during neoplasia or
inflammation (31, 32). HLA− DRlow monocytes also express less
CD4. Rigorous comparison of gating strategies has shown that
all monocytes may be collected using only HLA-DR, CD14, and
CD16 (32); here we show that a CD4 gate with a lower threshold
also captures the same events.
Bringing blood DC and monocyte subset analysis into routine
clinical practice will most likely reveal even greater variety and
subtlety of DC and monocyte deficiency states. New correlations
between human disease and the behavior of this compartment are
anticipated.
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